Knock-Down of Argonaute 2 (AGO2) Induces Apoptosis in Myeloid Leukaemia Cells and Inhibits siRNA-Mediated Silencing of Transfected Oncogenes in HEK-293 Cells

Basic and Clinical Pharmacology and Toxicology

Volumn 109, Issue 4, 2011, Pages 274-282

  Naoghare, Pravin K ^a,b   Tak, Yu Kyung ^a   Kim, Min Jung ^a   Han, Eunyoung ^a   Song, Joon Myong ^a  

^a Seoul National University   (South Korea)

^b NATIONAL ENVIRONMENTAL ENGINEERING RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

[(9,10 DIMETHOXY 3,3 DIMETHYL 7,7A,13,13ATETRAHYDRO 3H CHROMENO[3,4 B]PYRANO[2,3 H]CHROMEN 7 OL)]; ANTINEOPLASTIC AGENT; ARGONAUTE 2 PROTEIN; HISTONE DEACETYLASE 2; SH 03; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN A;

APOPTOSIS; ARTICLE; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SYNTHESIS; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA CELL; MYELOID LEUKEMIA; ONCOGENE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARGONAUTE PROTEINS; DRUG SCREENING ASSAYS, ANTITUMOR; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HEK293 CELLS; HISTONE DEACETYLASE 2; HUMANS; LEUKEMIA, MYELOID; ONCOGENES; RNA, SMALL INTERFERING; ROTENONE; TRANSFECTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 80052679906     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00716.x     Document Type: Article

References (35)

1. Wahid F, Shehzad A, Khan T, Kim YY. MicroRNAs: synthesis, mechanism, function, and recent clinical trials. Biochim Biophys Acta 2010;11:1231-43.
2. Katz M, Amit I, Yarden Y. Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta 2007;8:1161-76.
3. Manikandan J, Aarthi JJ, Kumar SD, Pushparaj PN. Oncomirs: the potential role of non-coding microRNAs in understanding cancer. Bioinformation 2008;2:330-4.
4. Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 2007;6:60.
5. Akao Y, Nakagawa Y, Hirata I, Iio A, Itoh T, Kojima K et al. Role of anti-oncomirs miR-143 and -145 in human colorectal tumors. Cancer Gene Ther 2010;17:398-408.
6. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 2005;65:9628-32.
7. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828-33.
8. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 2004;101:2999-3004.
9. Sonoki T, Iwanaga E, Mitsuya H, Asou N. Insertion of microRNA-125b-1, a human homologue of lin-4, into a rearranged immunoglobulin heavy chain gene locus in a patient with precursor B-cell acute lymphoblastic leukemia. Leukemia 2005;19:2009-10.
10. Izquierdo M. Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther 2005;12:217-27.
11. Gleave ME, Monia BP. Antisense therapy for cancer. Nature Rev Cancer 2005;5:468-79.
12. Zeng Y, Sankala H, Zhang X, Graves PR. Phosphorylation of Argonaute 2 at serine-387 facilitates its localization to processing bodies. Biochem J 2008;413:429-36.
13. Li L, Yu C, Gao H, Li Y. Argonaute proteins: potential biomarkers for human colon cancer. BMC Cancer 2010;10:38.
14. Cifuentes D, Xue H, Taylor DW, Patnode H, Mishima Y, Cheloufi S et al. A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. Science 2010;328:1694-8.
15. Dueck A, Meister G. MicroRNA processing without Dicer. Genome Biol 2010;11:123.
16. Bossé GD, Simard MJ. A new twist in the microRNA pathway: not Dicer but Argonaute is required for a microRNA production. Cell Res 2010;20:735-7.
17. Diederichs S, Haber DA. Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. Cell 2007;131:1097-108.
18. Bhalla KN, Fiskus W, Herger B, Rao R, Ustun C, Jillella A et al. Anti-leukemia activity of histone deacetylase (HDAC) inhibitor LBH589 involves depletion of EZH2 and DNA methyltransferase (DNMT) 1 through disruption of their chaperone association with heat shock protein (hsp) 90. J Clin Oncol 2007;25:18S.
19. Casalou C, Fragoso R, Nunes JF, Dias S. VEGF/PLGF induces leukemia cell migration via P38/ERK1/2 kinase pathway, resulting in Rho GTPases activation and caveolae formation. Leukemia 2007;21:1590-4.
20. Kim WY, Chang DJ, Hennessy B, Kang HJ, Yoo J, Han SH et al. A novel derivative of the natural agent deguelin for cancer chemoprevention and therapy. Cancer Prev Res (Phila Pa) 2008;1:577-87.
21. Naoghare PK, Kim MJ, Song JM. Uniform threshold intensity distribution-based quantitative multivariate imaging cytometry. Anal Chem 2008;80:5407-17.
22. Krek A, Grün D, Poy MN, Wolf R, Rosenberg L, Epstein EJ et al. Combinatorial microRNA target predictions. Nat Genet 2005;37:495-500.
23. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 2004;305:1437-41.
24. Vickers TA, Lima WF, Nichols JG, Crooke ST. Reduced levels of Ago2 expression result in increased siRNA competition in mammalian cells. Nucleic Acids Res 2007;35:6598-610.
25. Vire B, de Walque S, Restouin A, Olive D, Van Lint C, Collette Y. Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions. PLoS ONE 2009;4:e7085.
26. Bhalla KN, Nimmanapalli R, Fuino L, Tao J. Histone deacetylase inhibitor LAQ824 down regulates BCR-ABL levels and induces apoptosis of imatinib mesylate -sensitive or -refractory BCR-ABL positive human leukemia cells. Proc Am Soc Clin Oncol 2003;22:abstr 2322.
27. Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF, Kay NE. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia 2005;19:513-23.
28. Dias S, Shmelkov SV, Lam G, Rafii S. VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 2002;99:2532-40.
29. Koreth J, van den Heuvel S. Cell-cycle control in Caenorhabditis elegans: how the worm moves from G1 to S. Oncogene 2005;24:2756-64.
30. Chen D, Shan J, Zhu WG, Qin J, Gu W. Transcription-independent ARF regulation in oncogenic stress-mediated p53 responses. Nature 2010;464:624-7.
31. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al. A miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005;102:13944-9.
32. Michael MZ, O' Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol. Cancer Res 2003;1:882-91.
33. Naoghare PK, Ki HA, Paek SM, Tak YK, Suh YG, Kim SG et al. Simultaneous quantitative monitoring of drug-induced caspase cascade pathways in carcinoma cells. Integr Biol (Camb) 2010;2:46-57.
34. Matskevich AA, Moelling K. Stimuli-dependent cleavage of Dicer during apoptosis. Biochem J 2008;412:527-34.
35. Doench JG, Petersen CP, Sharp PA. siRNAs can function as miRNAs. Genes Dev 2003;17:438-42.